Aurobindo Phama’s consolidated net profit increased 32.5 per cent at ₹1,124 crore in the second quarter of the current financial year ended September 30, 2026, compared to ₹848 crore in the corresponding quarter of the previous financial year.
The total revenue of the Hyderabad-based company grew 24 per cent to ₹10,263 crore against ₹8,286 crore in the year-ago period. This was the highest-ever quarterly revenue, driven by growth across businesses.
“We are pleased to deliver a strong performance in Q2, reflecting the strength of our business fundamentals, sustained execution and the resilience of our diversified product portfolio. Our growth is supported by healthy organic momentum across our key businesses and the successful integration of inorganic opportunities, further strengthening our capabilities and positioning us for the future,’’ said K Nithyananda Reddy, Vice-Chairman and Managing Director, Aurobindo Pharma, in a release on Wednesday.
“As we advance our strategic priorities, we remain focused on sustainable growth, financial discipline and creating long-term value for our stakeholders, while continuing to expand access to quality and affordable healthcare worldwide,’’ he added.
Published on November 4, 2026
